Real-World Evidence Helps Open Accelerated Approval Pathway For Neurodegeneration Therapies

 
• By Bridget Silverman
  
Clene's ALS drug and uniQure's Huntington's disease gene therapy hope for a smooth road to accelerated approval despite the pathway's difficult history in neurodegenerative disease. (Shutterstock)

More from Real-World Evidence

More from R&D